|

Ligand Pharmaceuticals
Incorporated discovers, develops and markets new drugs for critical unmet
medical needs of patients principally in the areas of cancer, skin diseases,
and hormone-related diseases. Ligand has five drugs approved for marketing
in the U.S. ¾
Targretin® (bexarotene) capsules, Targretin® (bexarotene)
gel 1%, ONTAK® (denileukin diftitox) and Panretin® (alitretinoin)
gel 0.1%. A fifth product, AVINZA® (morphine sulfate
extended-release capsules), was recently approved for marketing by the FDA
in the U.S. |

  |